What has FDA cited under 21 CFR §211.165?

1 DSRV article cite 21 CFR §211.165. Enforcement cases behind them: FDA draft guidance on Real-Time Release Testing (pharmaceutical modernization initiative); ICH Q8 / Q10. Inspection exposure across them: 1 moderate.

What does DSRV recommend for 21 CFR §211.165?

From the newest article (FDA's Evolving Stance on Real-Time Release Testing (RTRT)): RTRT only reduces burden when the underlying control strategy and model maintenance are documented well enough to defend a release without end-product testing. DSRV's matching service is the Release Testing / RTRT Readiness, delivered through controlled intake at /submit. DSRV is decision support, not legal advice; verify against the official source each article names.

Browse by regulation1 article · 1 moderate

21 CFR §211.165

Every DSRV article whose Regulatory Snapshot cites 21 CFR §211.165: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set

What has FDA cited under 21 CFR §211.165?: 1 DSRV article cite 21 CFR §211.165. Enforcement cases behind them: FDA draft guidance on Real-Time Release Testing (pharmaceutical modernization initiative); ICH Q8 / Q10. Inspection exposure across them: 1 moderate.
What does DSRV recommend for 21 CFR §211.165?: From the newest article (FDA's Evolving Stance on Real-Time Release Testing (RTRT)): RTRT only reduces burden when the underlying control strategy and model maintenance are documented well enough to defend a release without end-product testing. DSRV's matching service is the Release Testing / RTRT Readiness, delivered through controlled intake at /submit. DSRV is decision support, not legal advice; verify against the official source each article names.

January 20269 min readModerate exposure
FDA's Evolving Stance on Real-Time Release Testing (RTRT)
The FDA has issued new draft guidance on RTRT as part of its modernisation initiative. We examine the regulatory pathway, technical requirements, and what this means for PAT-enabled manufacturing lines.
Case
FDA draft guidance on Real-Time Release Testing (pharmaceutical modernization initiative); ICH Q8 / Q10.
DSRV take
RTRT only reduces burden when the underlying control strategy and model maintenance are documented well enough to defend a release without end-product testing.

Address this risk

Release Testing / RTRT Readiness

Bring the document that has to hold up under 21 CFR §211.165. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR §211.165

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.